PEP02

DRUG4 trials

Sponsors

PharmaEngine

Conditions

Esophageal NeoplasmsMetastatic Colorectal CancerPancreatic NeoplasmsSolid TumorStomach Neoplasms

Phase 1

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

CompletedNCT00940758

PharmaEngineMetastatic Colorectal Cancer

Start: 2009-06-30End: 2014-06-30Updated: 2017-04-06

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

CompletedNCT02884128

PharmaEngineSolid Tumor

Start: 2006-01-31End: 2010-07-31Updated: 2016-08-30

Phase 2

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

CompletedNCT00813072

PharmaEngineEsophageal Neoplasms, Stomach Neoplasms

Start: 2007-11-30End: 2010-12-31Updated: 2012-03-02

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

CompletedNCT00813163

PharmaEnginePancreatic Neoplasms

Start: 2009-01-31End: 2012-07-31Updated: 2019-09-06

Related Papers

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

CPT Pharmacometrics & Systems Pharmacology2021-11-0911 citations

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

BMC Cancer2016-11-2137 citations